Sekar Kathiresan (Verve)
Looking to leapfrog antibodies and RNAi, Sekar Kathiresan says gene editing approach to cut PCSK9 looks durable
JP Morgan isn’t typically a data conference. But there are always exceptions for data that could make or break a company, piquing the interest of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.